4.7 Article

Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis

Journal

SCIENTIFIC REPORTS
Volume 8, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-018-20316-1

Keywords

-

Funding

  1. BBSRC-CASE studentship
  2. GlaxoSmithKline [BB/K501463/1]
  3. NIHR Clinician Scientist Fellowship (NIHR) [CS-2013-13-017]
  4. Biotechnology and Biological Sciences Research Council [1238336] Funding Source: researchfish

Ask authors/readers for more resources

Pulmonary fibrosis is a progressive scarring disorder of the lung with dismal prognosis and no curative therapy. Clusterin, an extracellular chaperone and regulator of cell functions, is reduced in bronchoalveolar lavage fluid of patients with pulmonary fibrosis. However, its distribution and role in normal and fibrotic human lung are incompletely characterized. Immunohistochemical localization of clusterin revealed strong staining associated with fibroblasts in control lung and morphologically normal areas of fibrotic lung but weak or undetectable staining in fibrotic regions and particularly fibroblastic foci. Clusterin also co-localized with elastin in vessel walls and additionally with amorphous elastin deposits in fibrotic lung. Analysis of primary lung fibroblast isolates in vitro confirmed the down-regulation of clusterin expression in fibrotic compared with control lung fibroblasts and further demonstrated that TGF-beta(1) is capable of down-regulating fibroblast clusterin expression. shRNAmediated down-regulation of clusterin did not affect TGF-beta(1)-induced fibroblast-myofibroblast differentiation but inhibited fibroblast proliferative responses and sensitized to apoptosis. Downregulation of clusterin in fibrotic lung fibroblasts at least partly due to increased TGF-beta(1) may therefore represent an appropriate but insufficient response to limit fibroproliferation. Reduced expression of clusterin in the lung may also limit its extracellular chaperoning activity contributing to dysregulated deposition of extracellular matrix proteins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers

Lena Schreiberhuber, Chiara Herzog, Charlotte D. Vavourakis, Elisa Redl, Christine Kastner, Allison Jones, Iona Evans, Michal Zikan, David Cibula, Peter Widschwendter, Karin Pfau, Barbara Math, Martin Seewald, Sylvain Amory, Peter Obrist, Martin Widschwendter

Summary: The majority of women with endometrial and cervical cancers experience abnormal vaginal bleeding, but only a small proportion of women with vaginal bleeding actually have these types of cancer. A new test called WID-qEC has been developed to accurately identify women with abnormal bleeding who may have endometrial or cervical cancer. This test shows high accuracy in detecting cervical cancer and performs better than cytology.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Rheumatology

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease

David Roofeh, Kevin K. Brown, Ella A. Kazerooni, Donald Tashkin, Shervin Assassi, Fernando Martinez, Athol U. Wells, Ganesh Raghu, Christopher P. Denton, Lorinda Chung, Anna-Maria Hoffmann-Vold, Oliver Distler, Kerri A. Johannson, Yannick Allanore, Eric L. Matteson, Leticia Kawano-Dourado, John D. Pauling, James R. Seibold, Elizabeth R. Volkmann, Simon L. F. Walsh, Chester Oddis, Eric S. White, Shaney L. Barratt, Elana J. Bernstein, Robyn T. Domsic, Paul F. Dellaripa, Richard Conway, Ivan Rosas, Nitin Bhatt, Vivien Hsu, Francesca Ingegnoli, Bashar Kahaleh, Puneet Garcha, Nishant Gupta, Surabhi Khanna, Peter Korsten, Celia Lin, Stephen C. Mathai, Vibeke Strand, Tracy J. Doyle, Virginia Steen, Donald F. Zoz, Juan Ovalles-Bonilla, Ignasi Rodriguez-Pinto, Padmanabha D. Shenoy, Andrew Lewandoski, Elizabeth Belloli, Alain Lescoat, Vivek Nagaraja, Wen Ye, Suiyuan Huang, Toby Maher, Dinesh Khanna

Summary: This study aimed to establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). The results showed that using the proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time.

RHEUMATOLOGY (2023)

Article Rheumatology

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial

Christopher P. Denton, Nicole S. Goh, Stephen M. Humphries, Toby M. Maher, Robert Spiera, Anand Devaraj, Lawrence Ho, Christian Stock, Elvira Erhardt, Margarida Alves, Athol U. Wells

Summary: Data from the SENSCIS trial suggests that patients with SSc-ILD are at risk of ILD progression and can benefit from nintedanib regardless of the extent of fibrotic ILD at baseline.

RHEUMATOLOGY (2023)

Article Critical Care Medicine

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Joshua J. Solomon, Sonye K. Danoff, Felix A. Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F. Dellaripa, Bibek Gooptu, Robert Vassallo, P. Gerard Cox, Kevin R. Flaherty, Huzaifa Adamali, Michael A. Gibbons, Lauren Troy, Ian A. Forrest, Joseph A. Lasky, Lisa G. Spencer, Jeffrey Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A. Perrella, David A. Lynch, Daniel C. Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary J. Goldberg, Ivan Rosas

Summary: This study evaluated the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). The results showed that although it did not meet the primary endpoint, pirfenidone slowed the rate of decline in lung function in patients with RA-ILD.

LANCET RESPIRATORY MEDICINE (2023)

Article Critical Care Medicine

Digital Technology and the Future of Interstitial Lung Diseases 1

Marlies S. Wijsenbeek, Catharina C. Moor, Kerri A. Johannson, Peter Jackson, Yet H. Khor, Yasuhiro Kondoh, Sujeet K. Rajan, Gabriela C. Tabaj, Brenda E. Varela, Pieter van der Wal, Richard N. van Zyl-Smit, Michael Kreuter, Toby M. Maher

Summary: The use of smartphones and the internet has facilitated self-monitoring and hybrid-care models, with the COVID-19 pandemic further fueling remote monitoring in interstitial lung diseases (ILDs). Home monitoring in ILD has the potential to enhance access to specialized care, alleviate healthcare system burdens, improve patient quality of life, identify disease deterioration, inform treatment decisions, and simplify clinical trials. However, there are challenges in terms of technical, analytical, and implementation issues. In this Series paper, experiences, challenges, and future perspectives of home monitoring in ILD are discussed.

LANCET RESPIRATORY MEDICINE (2023)

Article Critical Care Medicine

Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants

Anna L. Peljto, Rachel Z. Blumhagen, Avram D. Walts, Jonathan Cardwell, Julia Powers, Tamera J. Corte, Joanne L. Dickinson, Ian Glaspole, Yuben P. Moodley, Martina Koziar Vasakova, Elisabeth Bendstrup, Jesper R. Davidsen, Raphael Borie, Bruno Crestani, Philippe Dieude, Francesco Bonella, Ulrich Costabel, Gunnar Gudmundsson, Seamas C. Donnelly, Jim Egan, Michael T. Henry, Michael P. Keane, Marcus P. Kennedy, Cormac McCarthy, Aoife N. McElroy, Joshua A. Olaniyi, Katherine M. A. O'Reilly, Luca Richeldi, Paolo M. Leone, Venerino Poletti, Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Kokturk, Nesrin Mogulkoc, Christine A. Fiddler, Nikhil Hirani, R. Gisli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter D. Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena E. Foster, Kevin F. Gibson, Marilyn Glassberg, Daniel J. Kass, Jonathan A. Kropski, David Lederer, Angela L. Linderholm, Jim Loyd, Susan K. Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy J. Palmisciano, Cristina A. Reichner, Mauricio Rojas, Jesse Roman, Neil Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. A. Prele, Juan I. Enghelmayer, Maria Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Sterclova, Tewodros H. Gebremariam, Marjukka Myllarniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moises Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, Maria Molina-Molina, Lurdes Planas-Cerezales, Gunilla Westergren-Thorsson, Albert V. Smith, Ani W. Manichaikul, John S. Kim, Stephen S. Rich, Elizabeth C. Oelsner, R. Graham Barr, Jerome I. Rotter, Josee Dupuis, George O'Connor, Ramachandran S. Vasan, Michael H. Cho, Edwin K. Silverman, Marvin I. Schwarz, Mark P. Steele, Joyce S. Lee, Ivana V. Yang, Tasha E. Fingerlin, David A. Schwartz

Summary: This study investigated the role of rare variants, genome-wide, on the risk of idiopathic pulmonary fibrosis (IPF) using whole-genome sequencing. The results showed that rare variants within the TERT and RTEL1 genes were significantly associated with IPF, along with well-established common variants. Therefore, including TERT, RTEL1, common variants, and environmental risk factors in risk profiling and IPF therapy development is likely to have the largest impact on this complex disease.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Critical Care Medicine

Nocturnal Hypoxemia Associates With Symptom Progression and Mortality in Patients With Progressive Fibrotic Interstitial Lung Disease

Katherine J. Myall, Alex G. West, Jennifer L. Martinovic, Jodie L. Lam, Diana Roque, Zhe Wu, Toby M. Maher, Philip L. Molyneaux, Eui-Sik Suh, Brian D. Kent

Summary: Prolonged NH, but not OSA, is associated with worsening disease-related quality of life and increased mortality in patients with F-ILD.

CHEST (2023)

Article Respiratory System

The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study

Carl J. Reynolds, Fabiola Del Greco, Richard J. Allen, Carlos Flores, R. Gisli Jenkins, Toby M. Maher, Philip L. Molyneaux, Imre Noth, Justin M. Oldham, Louise Wain, Jiyuan An, Jue-Sheng Ong, Stuart MacGregor, Tom A. Yates, Paul Cullinan, Cosetta Minelli

Summary: Using bidirectional Mendelian randomisation (MR), it was found that gastro-oesophageal reflux disease (GORD) increases the risk of idiopathic pulmonary fibrosis (IPF), but there is no evidence that IPF increases the risk of GORD. This suggests that GORD should be considered in future studies of IPF risk and the mechanisms underlying the effect of GORD on IPF should also be investigated.

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Medicine, General & Internal

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis The ISABELA 1 and 2 Randomized Clinical Trials

Toby M. Maher, Paul Ford, Kevin K. Brown, Ulrich Costabel, Vincent Cottin, Sonye K. Danoff, Irene Groenveld, Eric Helmer, R. Gisli Jenkins, Julie Milner, Geert Molenberghs, Bjorn Penninckx, Matthew J. Randall, Bernt Van den Blink, Ann Fieuw, Charlotte Vandenrijn, Sanda Rocak, Ineke Seghers, Lixin Shao, Amit Taneja, Garrit Jentsch, Timothy R. Watkins, Wim A. Wuyts, Michael Kreuter, Nadia Verbruggen, Niyati Prasad, Marlies S. Wijsenbeek

Summary: This study aimed to assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF). The study found that ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Letter Respiratory System

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial

Maria Molina-Molina, Jessica Germaine Shull, Vanesa Vicens-Zygmunt, Pilar Rivera-Ortega, Katerina Antoniou, Francesco Bonella, Elisabetta Renzoni, Anne-Marie Russell, Toby M. Maher, Ada Vancheri, Anna Bachs, Victoria Aviles, Josep Palma, Guadalupe Bermudo, Guillermo Suarez-Cuartin, Cristian Tebe, Raul Rigo-Bonnin, Ana Montes-Worboys, Marlies Wijsenbeek, Carlo Vancheri

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Oncology

DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment

Chiara Herzog, Allison Jones, Iona Evans, Michal Zikan, David Cibula, Nadia Harbeck, Nicoletta Colombo, Angelique Floeter Radestad, Kristina Gemzell-Danielsson, Nora Pashayan, Martin Widschwendter

Summary: By analyzing DNA methylation and single nucleotide polymorphisms in cervical and breast tissues, it was found that a linear combination of methylation levels at breast cancer-associated methylation quantitative trait loci (mQTL) can be used to identify women with breast cancer. This method can be influenced by non-genetic risk factors and can be modified by preventive pharmacological intervention.

NPJ PRECISION ONCOLOGY (2023)

Article Respiratory System

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M. Maher, Fernando J. Martinez, Justin M. Oldham, Claudia Valenzuela, Maud Gordat, Yi Liu, Susanne Stowasser, Donald F. Zoz, Marlies S. Wijsenbeek

Summary: This article describes a pivotal phase III study of a novel treatment for idiopathic pulmonary fibrosis (IPF). The study examines the efficacy of an oral phosphodiesterase 4B inhibitor, BI 1015550, in preventing a decline in forced vital capacity (FVC) in patients with IPF. The primary endpoint of the trial is the absolute change in FVC at week 52, while the key secondary endpoint is a composite of time to first IPF exacerbation, hospitalization due to respiratory cause or death.

BMJ OPEN RESPIRATORY RESEARCH (2023)

Article Respiratory System

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial

Michael Kreuter, Elisabeth Bendstrup, Stephane Jouneau, Toby M. Maher, Yoshikazu Inoue, Corinna Miede, Dirk Lievens, Bruno Crestani

Summary: This study analyzed the relationship between baseline BMI and weight change and outcomes in patients with pulmonary fibrosis. The results showed that lower BMI and weight loss were associated with worse prognosis, indicating the need for measures to prevent weight loss.

RESPIRATORY RESEARCH (2023)

Article Respiratory System

The Burden and Impact of Cough in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the Prospective Observational PROFILE Study

Peter Saunders, Zhe Wu, William A. Fahy, Iain D. Stewart, Gauri Saini, David J. F. Smith, Rebecca Braybrooke, Carmel Stock, Elisabetta A. Renzoni, Simon R. Johnson, R. Gisli Jenkins, Maria G. Belvisi, Jaclyn A. Smith, Toby M. Maher, Philip L. Molyneaux

Summary: This study aims to assess the burden of cough and its impact on quality of life in newly diagnosed IPF patients. The results indicate that cough burden in IPF is high, but cough-specific quality of life does not have prognostic value and is not associated with MUC5B promoter polymorphism.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2023)

Meeting Abstract Respiratory System

Nalbuphine Extended Release Treatment Achieved Rapid and Sustained Reduction in Reported Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis

Toby M. Maher, Thomas Sciascia, Enoch Bortey, Philip L. Molyneaux, Marlies Wijsenbeek, Jaclyn Smith

No Data Available